Tisch Cancer Institute at Mount Sinai

 

ASH 2021 Conference Coverage on VuMedi
Avatar

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
617 views
December 15, 2021
Comments 0
Login to view comments. Click here to Login
Videos
15:23

New

Non Immune-Based Approaches for Advanced Myeloma

Tisch Cancer Institute at Mount Sinai

G. Kaur

06:30

ASTRO 2023 Insights: "Treatment Landscape for mCRPC - Lu-177-PSMA, R…

Tisch Cancer Institute at Mount Sinai

W. Oh

201 views
10:51

SOHO 2023 Next Questions: Myeloproliferative Neoplasms

SOHO 2023 Eleventh Annual Meeting

J. Mascarenhas

64 views
17:34

SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis

SOHO 2023 Eleventh Annual Meeting

J. Mascarenhas

228 views
01:07

Lecture Summary - WCLC 2022 on Cancer and Atopy: Parallel Drivers? I…

WCLC 2022 Conference Coverage

T. Marron

13 views
11:14

WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Syner…

WCLC 2022 Conference Coverage

T. Marron

51 views
09:41

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofi…

i3 Health

J. Mascarenhas

94 views
05:07

TKI in the Management of Advanced HCC

Icahn School of Medicine at Mount Sinai

A. Villanueva

233 views
11:42

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Icahn School of Medicine at Mount Sinai

M. Kremyanskaya

73 views
04:20

The Roles of Etiology and Biopsy in Hepatocellular Carcinoma

Oncology Data Advisor

A. Villanueva

34 views
20:43

PD-L1 Expression: Practical Implications in Advanced Stage NSCLC

Tisch Cancer Institute at Mount Sinai

F. Hirsch

195 views
07:13

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

156 views
06:20

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

115 views
05:04

ASCO GI 2022 Updates on IO for Early Stage HCC

ASCO GI 2022 Conference Coverage

A. Villanueva

172 views
15:25

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

ASH 2021 Conference Coverage on VuMedi

M. Kremyanskaya

88 views
07:56

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

52 views
05:15

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

617 views
21:07

Persistent Leukocytosis and PV Progression: Prognostic and Therapeut…

2021 International Congress on Myeloproliferative Neoplasms

J. Mascarenhas

14 views
01:47

2021 ASCO Summary on COVID-19 & Cancer

2021 ASCO Virtual Direct™ Highlights

D. Doroshow

9 views
08:32

2020 NSCLC Update: Does PD-L1 Predict Pembrolizumab Response in Pati…

Tisch Cancer Institute at Mount Sinai

D. Doroshow

164 views
06:49

Can Pacritinib Be Used to Treat Cytokine Storm in Patients With COVI…

Tisch Cancer Institute at Mount Sinai

J. Mascarenhas

3.1K views
28:34

Managing Hepatocellular Carcinoma: Early Detection and Diagnosis, St…

Tisch Cancer Institute at Mount Sinai

A. Villanueva

364 views
07:57

Epidemiology of Hepatocellular Carcinoma: Disease Burden and Trends

Tisch Cancer Institute at Mount Sinai

A. Villanueva

85 views
11:35

Clinical Challenges in Management of Hepatocellular Carcinoma: Liqui…

Tisch Cancer Institute at Mount Sinai

A. Villanueva

53 views
24:22

Update on Clinical Trials in Myeloproliferative Neoplasms

Tisch Cancer Institute at Mount Sinai

J. Mascarenhas

393 views